Stocks
Funds
Screener
Sectors
Watchlists
CRMD

CRMD - CorMedix Inc Stock Price, Fair Value and News

$6.45+0.05 (+0.78%)
Market Closed

92/100

CRMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

92/100

CRMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CRMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRMD Price Action

Last 7 days

-0.1%

Last 30 days

-13.2%

Last 90 days

-43.9%

Trailing 12 Months

-37.9%

CRMD RSI Chart

CRMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CRMD Valuation

Market Cap

509.9M

Price/Earnings (Trailing)

3.13

Price/Sales (Trailing)

1.64

EV/EBITDA

2.42

Price/Free Cashflow

2.95

CRMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CRMD Fundamentals

CRMD Revenue

Revenue (TTM)

311.7M

Rev. Growth (Yr)

312.1%

Rev. Growth (Qtr)

23.34%

CRMD Earnings

Earnings (TTM)

163.1M

Earnings Growth (Yr)

4.13%

Earnings Growth (Qtr)

-87.09%

CRMD Profitability

Operating Margin

92.90%

EBT Margin

48.13%

Return on Equity

40.23%

Return on Assets

19.74%

Free Cashflow Yield

33.89%

CRMD Investor Care

Shares Dilution (1Y)

29.85%

Diluted EPS (TTM)

1.98

CRMD Alerts

  • Big jump in Revenue (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202582.6M121.5M214.3M311.7M
20240863.9K12.3M43.5M
202227.2K39.9K52.7K65.4K
2021253.4K245.2K190.3K14.4K
2020193.6K174.8K208.3K239.2K
2019570.3K598.0K285.0K283.3K
2018313.0K184.4K495.8K429.8K
2017222.2K341.9K358.5K329.3K
2016220.3K116.8K125.3K224.1K
2015208.3K288.6K272.1K210.1K
2014000189.3K
20130000
CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
 CEO
 WEBSITEcormedix.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES40

CorMedix Inc Frequently Asked Questions


CRMD is the stock ticker symbol of CorMedix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of CorMedix Inc is 509.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CRMD's PE ratio (Price to Earnings) is 3.13 and Price to Sales (PS) ratio is 1.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRMD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, CorMedix Inc has provided -0.055 (multiply by 100 for percentage) rate of return.